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Abstract
Objective—Routine monitoring of plasma HIV RNA among HIV-infected patients on 
antiretroviral therapy (ART) is unavailable in many resource-limited settings. Alternative 
monitoring approaches correlate poorly with virologic failure and can substantially delay switch to 
second-line therapy. We evaluated the impact of delayed switch on mortality among patients with 
virologic failure in Africa.
Design—A cohort.
Methods—We examined patients with confirmed virologic failure on first-line non-nucleoside 
reverse transcriptase inhibitor (NNRTI)-based regimens from four cohorts with serial HIV RNA 
monitoring in Uganda and South Africa. Marginal structural models aimed to estimate the effect 
of delayed switch on mortality in a hypothetical trial in which switch time was randomly assigned. 
Inverse probability weights adjusted for measured confounders including time-updated CD4+ T-
cell count and HIV RNA.
Results—Among 823 patients with confirmed virologic failure, the cumulative incidence of 
switch 180 days after failure was 30% [95% confidence interval (CI) 27–33]. The majority of 
patients (74%) had not failed immunologically as defined by WHO criteria by the time of 
virologic failure. Adjusted mortality was higher for individuals who remained on first-line therapy 
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than for those who had switched [odds ratio (OR) 2.1, 95% CI 1.1 –4.2]. Among those without 
immunologic failure, the relative harm of failure to switch was similar (OR 2.4; 95% CI 0.99–5.8) 
to that of the entire cohort, although of borderline statistical significance.
Conclusion—Among HIV-infected patients with confirmed virologic failure on first-line ART, 
remaining on first-line therapy led to an increase in mortality relative to switching. Our results 
suggest that detection and response to confirmed virologic failure could decrease mortality.
Keywords
antiretroviral; cohort studies; HIV; HIV RNA level; inverse probability weight; marginal 
structural model; time-dependent confounding; treatment failure; viral load
Introduction
First-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens save the 
lives of millions of HIV-infected patients globally; however, resistance to these regimens 
results in increased viral replication (virologic failure). In resource-rich settings, HIV RNA 
levels are monitored regularly and the threshold to switch regimens after virologic failure is 
detected is low [1]. However, in Africa, delayed switch following failure is common due to 
several factors. First, routine plasma HIV RNA monitoring is often unavailable and 
alternative CD4+ T-cell and clinical criteria provide poor surrogates [2–7]. Second, until 
recently, WHO guidelines suggested that HIV RNA levels below 5000 or 10000 copies/ml 
did not warrant immediate regimen switch [8,9]. Third, second-line regimens are expensive, 
and in the absence of compelling data that switching immediately is needed, the resources to 
fund such regimens have been limited. Finally, when patients have confirmed HIV RNA 
rebound, clinicians may be hesitant to switch patients with perceived poor adherence.
Although delayed switch following virologic failure exposes patients to accumulation of 
resistance mutations and advanced immunosuppression, the clinical effect of delayed switch 
in resource-limited settings has not been adequately quantified [10–13]. To date, four 
randomized trials found no significant reduction in mortality among individuals monitored 
with routine HIV RNA compared to those with access to clinical monitoring only, CD4+ and 
clinical monitoring, or CD4+ and clinical monitoring with discretionary HIV RNA levels 
[14–18]. However, the excellent adherence and limited follow-up time in these studies, and 
thus few virologic failures and deaths, resulted in attenuated power.
There are several lines of indirect evidence that routine HIV RNA monitoring and prompt 
switching are important. In multisite observational studies in southern Africa, patients 
treated in programmes with routine HIV RNA monitoring had higher switch rates, higher 
CD4+ T-cell counts at switch and lower mortality than patients treated in programmes 
without routine HIV RNA levels [19,20]; however, clinics with HIV RNA testing may have 
had additional resources or infrastructure, confounding observed associations. Delayed 
switch following failure has been associated with lower rates of virologic suppression on 
second-line therapy in South Africa; however, prior analyses did not quantify mortality 
impact nor did they adjust for confounding by time-updated CD4+ cell count, HIV RNA 
level or other factors [21].
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In order to evaluate the impact of delayed switch to second-line therapy following confirmed 
virologic failure on mortality in Africa, we used data from adult patients treated with first-
line NNRTI-based antiretroviral therapy (ART) in four African clinics where serial HIV 
RNA monitoring was carried out. We analysed a large number of patients with confirmed 
virologic failure treated in routine care settings and controlled in analysis for clinic. Finally, 
we used inverse probability weights to adjust for confounding by time-varying CD4+ T-cell 
count and plasma HIV RNA level, factors that are affected by prior antiretroviral treatment 
and thus not amenable to traditional regression-based adjustment [22].
Materials and methods
Patient population
We examined data from HIV-infected adults who initiated first-line NNRTI-based ART 
between 2002 and 2011 in one of four prospective cohorts: Uganda AIDS Rural Treatment 
Outcomes (UARTO), a research cohort in Mbarara, Uganda; Infectious Diseases Institute 
(IDI), a research cohort in Kampala, Uganda; Rakai Health Sciences Program (RHSP), a 
clinic-based cohort in Rakai, Uganda; and, Gugulethu, a clinic-based cohort in Cape Town, 
South Africa. At the time of analysis, UARTO included 484 ART initiators, RHSP included 
1665 initiators, IDI included 559 initiators and Gugulethu included 5267 initiators. Patients 
followed in these cohorts were managed by clinics that followed concurrent WHO 
guidelines. All cohorts serially measured plasma HIV RNA level.
Measurements
Patients who experienced confirmed virologic failure while on first-line NNRTI-based 
ARTwere included in primary analyses. Virologic failure could occur any time at least 16 
weeks after ART initiation and was defined as two consecutive ‘failing’ HIV RNA levels 
measured fewer than 270 days apart. HIV RNA levels measured between 12 and 24 weeks 
after ART initiation were classified as ‘failing’ if they were more than 1000 copies/ml; HIV 
RNA levels measured after 24 weeks of ART were classified as failing if they were more 
than 400 copies/ml [11]. In sensitivity analyses, we analysed patients with confirmed 
rebound (confirmed virologic failure with at least one prior HIV RNA level <400 copies/ml) 
and unconfirmed rebound (a single HIV RNA level ≥400 copies/ml with at least one prior 
HIV RNA level <400copies/ml).
Secondary analyses evaluated patients without immunological failure prior to or concurrent 
with virologic failure. Immunologic failure was defined as meeting either of the WHO 2013 
criteria: CD4+ cell count less than or equal to pretherapy baseline or CD4+ cell count less 
than 100 cells/μl after at least 6 months of ART [9]. In addition to serial HIV RNA and 
CD4+ cell count measurements, all cohorts recorded age, sex and clinical stage at ART 
initiation. Switch to second-line therapy was defined as initiation of a protease inhibitor 
(boosted lopinavir). Deaths were ascertained via linkage to a national death registry 
(Gugulethu) or active tracking in the community (the East African cohorts).
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Ethics
The study was approved by all appropriate local and national Institutional Review Boards. 
Analyses were conducted with de-identified data.
Analysis
Time zero was defined as date of virologic failure confirmation. Cumulative incidence of 
switch to second-line therapy following confirmed virologic failure was estimated treating 
death as a competing event [23,24]. For remaining analyses, data were discretized into 30-
day intervals, with time-varying variables coded as the most recent measurement available 
to guide clinical decision-making at the start of an interval. Unadjusted associations of each 
potential confounder with mortality and switch were calculated using pooled logistic 
regression models with robust standard error estimates to account for repeated measures 
[25].
Marginal structural models were used to investigate how delayed switch to second-line 
therapy impacted mortality over time. Analyses targeted a hypothetical trial in which 
individuals were enrolled at the time of confirmed failure and were assigned a random 
switch time, ranging from switch immediately (first 30 days following confirmation of 
failure) to never switch. Marginal structural models were used to summarize how use of first 
versus second-line therapy (switch status) at the end of an interval affected probability of 
dying in the following interval [11,22,26]. We fit pooled logistic regression models that 
included time since failure and switch status as main terms, as well as models with an 
additional interaction term between time and switch status and models with a natural cubic 
spline on time with knots at the 25th, 50th, and 75th percentiles.
Several time-varying variables, including CD4+ cell count, HIV RNA and clinic visit 
frequency, influence decisions whether and when to switch therapy, as well as affecting 
mortality; thus adjustment for confounding by these variables is needed. These same 
variables, however, are affected by prior switching decisions and mediate the effect of 
exposure to failing first-line therapy on mortality. Hence, adjustment via standard regression 
will bias results [11,22,26]. Inverse probability weighting (IPW) was therefore used to adjust 
for measured confounders [22,27].
In primary analyses, individuals were censored at reported transfer to an outside clinic or 
database closure, an appropriate approach under the assumptions of complete death 
ascertainment and transfer reporting. In secondary analyses, we relaxed this assumption by 
censoring at the first of database closure, transfer or 270 days without a recorded visit or 
laboratory test, with 270 chosen to reflect at least two consecutive missed visits and to 
reduce censoring of patients with a missed visit who subsequently returned to care. An 
additional weight was used to adjust for measured sources of potentially informative 
censoring, with separate components for each cause of censoring.
All treatment and censoring weights were estimated using Super Learner, a data adaptive 
approach that used 10-fold cross-validation to learn the optimal weighted combination of a 
library of algorithms [28]. The library included multivariate adaptive polynomial spline 
regression combined with initial screening to limit adjustment variables to those either 
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associated with mortality (P < 0.2) or considered a priori to be important confounders 
(CD4+ cell count, HIV RNA level and clinic), as well as five candidate parametric logistic 
regression models a priori specified on the basis of background knowledge [29–31]. The set 
of candidate confounders included clinic, age, sex, baseline WHO stage, calendar date of 
failure, virologic suppression prior to failure, CD4+ cell count and HIV RNA level at the 
time of failure and a range of time-varying summaries (including nadirs, zeniths and change 
over time) of CD4+ cell count, HIV RNA level and recorded visit frequency (Table 2). In 
sensitivity analysis, we excluded WHO stage at ART initiation from the adjustment set.
All weights were stabilized [22]. Standard errors were estimated using the robust sandwich 
estimator [25].
Results
Among 7975 patients on first-line NNRTI-based ART, 823 patients experienced confirmed 
virologic failure. Among these patients, 52% of first-line regimens contained efavirenz and 
48% contained nevirapine. Of the 358 patients who had their therapy switched to second-
line protease inhibitor based ART, the median time to switch was 116 days after 
confirmation of failure [interquartile range (IQR) 63–198 days]. Cumulative incidence of 
switch by 30, 90 and 180 days after failure was 3% [95% confidence interval (CI) 2–4], 16% 
(95% CI 14–19) and 30% (95% CI 27–33), respectively (Fig. 1a). Most patients (74%) had 
not failed immunologically (as defined by WHO criteria) by the time of virologic failure; 
140 individuals (17% of failures) experienced at least one HIV RNA level less than 400 
copies/ml after confirmed failure and while still on first-line therapy.
Among 823 patients with confirmed failure, a median of 79 days passed between first and 
confirmatory failing HIV RNA levels (IQR 53–115 days). The confirmatory failing HIV 
RNA measurement occurred a median of 1.4 years after ART initiation (IQR 0.8–2.6 years). 
Median values at the time of failure were 220 CD4+ T cells/μl and 6214 plasma HIV RNA 
copies/ml; 197 (24%) of individuals with confirmed virologic failure had not previously 
suppressed HIV RNA level below 400 copies/ml (Table 1).
Predictors of switch and mortality
In unadjusted analyses, switch to second-line therapy was associated with lower CD4+ cell 
count at treatment initiation and most recent measurement, lower nadir and peak CD4+ cell 
counts (including CD4+ cell count prior to ART initiation), greater percentage decline in 
CD4+ cell count since failure, higher HIV RNA level at most recent measurement, higher 
nadir HIV RNA level, baseline WHO clinical stage III or IV, and shorter duration between 
ART start and virologic failure (Table 2).
We observed 49 deaths among 823 persons, followed for a median of 2.1 years after failure 
(2.5 deaths per 100 person-years, Fig. 1b); 32 deaths (65%) occurred while still on first-line 
ART. Median CD4+ cell count at death was 107 cells/μl (IQR 46–211 cells/μl), measured a 
median of 90 days before death (IQR 34–136 days). Of the 17 deaths after switch, 14 had an 
HIV RNA level measured after switch. Of these, last measured HIV RNA level, measured a 
median of 134 days before death (IQR 72–205 days), was less than 400 copies/ml for four 
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patients and less than 1000 copies/ml for seven patients. In unadjusted analyses, significant 
predictors of mortality included lower CD4+ cell count at the most recent measurement, 
lower nadir CD4+ cell count, greater percentage decline in CD4+ cell count since failure, 
higher HIV RNA level at the most recent measurement and at the time of failure, higher 
nadir and peak HIV RNA level, older age, male sex and recorded visit within prior 90 days 
(Table 2).
Before adjustment for confounding, the discrete hazard of death was not significantly 
different among patients who remained on first-line therapy compared with patients who had 
switched. Assuming a constant relative odds over time, the relative odds of death among 
individuals on first-line therapy was 1.5 (95%CI 0.8, 2.6) compared with those on second-
line. When an interaction term between switching status and time was included, remaining 
on first-line therapy was associated with elevated mortality, although the magnitude of this 
association declined nonsignificantly over time (Table 3).
Estimated effect of delayed switch
Adjustment for measured confounders increased the estimated magnitude of harm due to 
delayed switch (Table 3). Assuming a constant relative odds over time, the adjusted relative 
odds of death among individuals still on first-line therapy compared with those who had 
switched was 2.1 (95% CI 1.1–4.2). When an interaction term between switching status and 
time was included, for the first 28 months following failure those individuals who remained 
on first-line therapy had a higher probability of dying than those who had switched; the 
protective effect of switch declined nonsignificantly over time since failure (P = 0.09) 
(Table 3, Fig. 2a). Exclusion of the 197 patients without at least one HIV RNA level less 
than 400 copies/ml prior to failure resulted in similar estimates (Table 3). Inclusion of time 
since failure as a restricted cubic spline and exclusion of baseline stage from the adjustment 
set had a minimal impact on all estimates (data not shown).
The majority of patients (74%) had not failed immunologically (as defined by WHO criteria) 
by the time of virologic failure. Median CD4+ cell count among these 610 patients at 
virologic failure was 258 cells/μl (IQR 179–340 cells/μl). Among the 293 who subsequently 
switched, median CD4+ cell count at switch was 253 cells/μl (IQR: 168–328 cells/μl). 
Seventy-one of these patients subsequently failed immunologically and 27 died. Among the 
15 patients who died on first-line therapy, median CD4+ cell count at death was 107 cells/μl 
(IQR 48–209 cells/μl), measured a median of 90 days before death. Among the 12 patients 
who died on second-line therapy, median CD4+ cell count at death was 124 cells/μl (IQR 
35–264 cells/μl), measured a median of 183 days before death. After adjustment for 
measured confounders of switch, estimated mortality in this subpopulation was lower than in 
the full cohort (Fig. 2b). Assuming a constant relative odds over time, the adjusted relative 
odds of death among individuals still on first-line therapy compared to those who had 
switched was 2.4 (95% CI 0.99–5.8), similar to that of the full cohort, although of borderline 
significance (P= 0.052) (Table 3).
Three hundred and fifty-one (43%) patients experienced at least one episode of 270 days or 
more without a recorded visit, a median of 510 days after virologic failure (IQR 300–855 
days). Using this definition of ‘loss to follow up’, 39 deaths prior to loss, transfer or 
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database closure were observed. The estimated effect of delayed switch was similar to 
estimates that censored only at database closure or reported transfer (Table 3).
Nonconfirmed virologic rebound, defined as a single HIV RNA level of at least 400 
copies/ml with at least one preceding HIV RNA level less than 400 copies/ml, was observed 
in 1337 patients. Of these, 1153 (86%) had at least one subsequent HIV RNA level 
measured on first-line therapy, measured a median of 84 days after initial unsuppressed HIV 
RNA level (IQR 56–126 days). The majority (55%) of these confirmatory RNA levels were 
less than 400 copies/ml. Among individuals with nonconfirmed rebound, in both unadjusted 
and adjusted analyses mortality was no higher among individuals who remained on first-line 
therapy than among those on second-line (Table 3).
Discussion
When to switch therapy for treatment ‘failure’ in resource-poor regions remains 
controversial. Much of the debate has been informed by cost concerns and practical issues, 
as well as by several randomized clinical studies in which most patients did well and follow-
up time was limited (median 1.5–3 years following ART initiation), making it hard to 
evaluate clinical outcomes among the small numbers of failures [14–18]. In this study, we 
identified a large number of individuals with confirmed virologic failure in routine clinical 
practice, followed for a median of 4.3 years after ART initiation (2.2 years after confirmed 
failure). We found that switching to second-line protease inhibitor based therapy was 
delayed in many patients, a practice that others have found to be common, even in settings 
in which routine HIV RNA monitoring and second-line therapy are available [32–35]. We 
found, after adjustment for measured confounders, that remaining on first-line therapy 
following confirmed virologic failure significantly increased mortality. The estimated effect 
of delayed switch was similar among individuals without evidence of immunologic failure at 
the time of virologic failure, although of borderline statistical significance.
Several factors may have contributed to delayed switch in our study cohorts. First, clinician 
access to HIV RNA results was likely delayed in many cases, particularly in cohorts in 
which HIV RNA levels were drawn for research purposes. Second, during much of the study 
period, the WHO recommended an HIV RNA threshold of 5000 or 10 000 copies/ml, ideally 
with confirmation, for switching [8,9]. Third, clinicians may have delayed switch in patients 
with perceived adherence lapses or with tuberculosis treated with rifampicin due to concern 
for pharmacological interactions with ritonavir, or may have prioritized use of costly and 
scarcer second-line drugs for patients deemed most likely to benefit. Fourth, initiation of 
second-line therapy may have required scheduling and attendance at a subsequent visit.
We required confirmation of failure in order to improve specificity for true virologic failures 
rather than ‘blips’ or falsely elevated HIV RNA levels due to laboratory error [36]. Among 
patients who achieved a suppressed HIV RNA level, the majority of initial HIV RNA 
measurements of at least 400 copies/ml were followed by a consecutive HIV RNA 
measurement of less than 400 copies/ml, and we were unable to detect any effect of delayed 
switch on mortality among patients with nonconfirmed virologic rebound. These 
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observations support the use of a confirmatory HIV RNA level for switching, at least at the 
lower threshold for suppression [37].
Patients in our cohort initiated ART at low CD4+ cell counts. This may have contributed to 
high mortality resulting from failure to switch. The impact of delayed switch following 
confirmed virologic failure may differ among patients initiating ART more recently and at 
higher CD4+ cell counts.
As has been observed by others, a substantial proportion of individuals with confirmed 
failure had at least one subsequent HIV RNA level of less than 400 copies/ml while still on 
first-line therapy [17,34]. In the absence of resistance testing, which is unlikely to be widely 
available in this region, any definition of virologic failure will include some patients with 
transient loss of suppression. Our analyses suggest that in the absence of resistance testing, 
prompt switch to second-line therapy following confirmed failure has the potential to save 
lives.
Our estimates of the impact of delayed switch on mortality rely on measured variables to 
adjust for confounding. We were not able to adjust for time-updated WHO stage following 
ART initiation, as this measure was not introduced until 2010 and remains inconsistently 
applied in practice [8]. Sensitivity analyses excluding baseline WHO stage from the 
adjustment set had a minimal impact on estimates, suggesting that the baseline measure 
provides little additional confounding control after other measured covariates (including 
serial CD4+ cell count and HIV RNA) are adjusted for. However, unmeasured confounding 
by disease severity and perceived adherence not captured by CD4+ cell count and HIV RNA 
measures might result in either under or overestimates of the harm of delayed switch.
Nonetheless, use of inverse probability of treatment weighting rather than standard 
regression made it possible to adjust for measured sources of time-varying confounding and 
informative censoring, including serial CD4+ cell counts and HIV RNA levels (the latter of 
which correlates with adherence). We further minimized potential bias due to model 
misspecification through use of data-adaptive methods when estimating the weights and 
through use of alternative marginal structural model specifications in sensitivity analyses 
[28]. Further, although all cohorts had some form of active outcome ascertainment, both 
death ascertainment and transfer reporting may have been incomplete, resulting in bias not 
amenable to adjustment without supplementary data [38]. Sensitivity analyses in which 
patients were censored after 270 days without a clinic visit resulted, however, in similar 
estimates of increased mortality due to delayed switch.
We investigated the potential benefit of routine HIV RNA level monitoring compared with 
CD4+ cell count monitoring alone by estimating the effect of delayed switch among patients 
who had not met WHO immunologic failure criteria by the time of confirmed virologic 
failure, and thus who would not yet have been switched under CD4+ cell count criteria. 
Point estimates of the effect of delayed switch in these patients were similar to the larger 
group, but had less statistical precision. These secondary analysis are subject to several 
limitations, however. First, we had limited power to detect an effect in this subgroup. 
Second, these analyses do not directly quantify the impact of routine HIV RNA level 
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monitoring, as data were not available to assess WHO clinical failure criteria, and a minority 
of patients subsequently failed immunologically and thus would have experienced a delayed 
switch with CD4+ cell count monitoring alone. Although dynamic regime methods address 
the latter concern, they typically require larger samples [39,40]. Third, our analyses 
underestimate the benefits of routine viral monitoring in that they do not account for 
reduction in unneeded switches due to poor specificity of immunologic failure criteria, 
improved opportunity for targeted adherence interventions, decreased acquired and 
transmitted resistance, or reduced infectivity [3,7,41–44]. Although simulation models can 
investigate these broader health, transmission and costing implications, such models rely on 
understanding the mortality impact of deferred switch following virologic failure; our 
analyses contribute to this knowledge base [45–49].
Conclusion
To the best of our knowledge, our study is the first to estimate the impact of delayed switch 
to second-line therapy following confirmed virologic failure on mortality among patients 
treated in a resource-limited setting, taking into account time-varying confounders of 
switching. Many individuals did not switch to second-line therapy following confirmation of 
virologic failure, or switched only after substantial delay, and these delays increased 
mortality relative to immediate switch. Our findings support the importance of detection and 
response to virologic failure.
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Fig. 1. Cumulative incidence of switch to second-line antiretroviral therapy (ART) (a) and 
mortality (b) following confirmed virologic failure on first-line NNRTI-based ART, among 823 
patients with confirmed virologic failure, overall and stratified by WHO immunological failure 
at or before time of virologic failure
N refers to full cohort (not stratified by immunologic failure).
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Fig. 2. Counterfactual mortality curves following confirmed virologic failure on first-line 
NNRTI-based ART, estimated using inverse probability weighting of marginal structural models
(a) Among all patients with confirmed virological failure (N=823) under a range of 
hypothetical delays before switching to second-line antiretroviral therapy, ranging from 
immediate switch (within 30 days of confirmed virologic failure) to never switch, (b) 
Among all patients with confirmed virological failure (N=823) and only those patients 
without WHO immunological failure at or before time of virologic failure (N=610), under 
immediate switch (within 30 days of confirmed virologic failure) and never switch.
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Table 2
Unadjusted predictors of switch to second-line antiretroviral therapy and mortalitya
Relative odds of switch (95% CI) Relative odds of death (95% CI)
Age (per 10 years) 0.91 (0.78–1.07) 1.80* (1.30–2.51)
Male sex 0.81 (0.62–1.05) 1.93* (1.09–3.43)
CD4+ T cell count (per 100 cells/μl)
 At ART start 0.71* (0.62–0.81) 0.95 (0.69–1.30)
 Nadir 0.66* (0.55–0.78) 0.56* (0.36–0.88)
 Peak 0.88* (0.83–0.94) 0.87 (0.73–1.05)
 At virologic failure 0.95 (0.87–1.04) 0.77 (0.56–1.06)
 Most recent measurement 0.86* (0.80–0.94) 0.53* (0.37–0.76)
CD4+ cell count decline since failure (per 10%) 1.06* (1.01–1.11) 1.17* (1.09–1.27)
Plasma HIV RNA level (per log 10copies/ml)
 At virologic failure 1.11 (0.98–1.26) 1.78* (1.22,–2.61)
 Peak 0.94 (0.76–1.15) 2.79* (1.71–4.57)
 Nadir 1.13* (1.03–1.24) 1.41* (1.04–1.91)
 Most recent measurement 1.57* (1.43–1.73) 2.02* (1.50–2.74)
Suppression prior to failureb 0.86 (0.66–1.12) 1.00 (0.53–1.88)
WHO clinical stage at ART Start
 Stage I/II Ref Ref
 Stage III/IV 1.51* (1.17–1.95) 2.52 (0.98–6.46)
ART start to failure (per 180 days) 0.91* (0.87–0.96) 1.01 (0.91–1.13)
Seen in prior 90-day interval 0.89 (0.71–1.11) 1.82* (1.02–3.27)
Time since last recorded visit (per 180 days) 0.87 (0.66–1.15) 0.68 (0.46–1.02)
ART, antiretroviral therapy; CI, confidence interval.
*
P<0.05.
a
In addition to the above variables, candidate predictors for estimated switching and censoring weights included: square root and categorical 
transformations of CD4+ cell count values; categorical transformations of HIV RNA values; indicators of whether an HIV RNA or CD4+cell count 
test was performed in the previous 90-day interval; WHO immunologic failure criteria; time since failure; calendar date of failure; and clinic.
b
Defined as at least one HIV RNA ≤400copies/ml after starting ART and prior to confirmed failure.
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Table 3
Unadjusted and inverse probability weighted estimates of the association between switch 
to second-line therapy following confirmed virologic failure and mortalitya
Patient population/censoring definition Main term modelb
Model including 
interaction with timec
Main term for switch status (OR 
for mortality on first-line versus 
second-line therapy)d (95% CI); 
P value
Main term for switch 
statuse (95% CI); P 
value
Interaction term between 
switch status and time 
since failuref (95% CI); 
P value
Confirmed virologic failure (N = 823)g Unadjusted: 1.47 (0.83–2.60); P = 0.19
Unadjusted: 3.19 (1.24–
8.20); P = 0.016
Unadjusted: 0.95 (0.90–
1.00); P = 0.068
IPW: 2.12 (1.09– 4.15); P = 0.027 IPW: 4.18 (1.54–11.32); P = 0.005
IPW: 0.95 (0.90–1.01); P 
= 0.086
Confirmed virologic failure (N = 823); censored 
at 9 months without visith
Unadjusted: 1.75 (0.89–3.42); P = 
0.10
Unadjusted: 3.62 (1.28–
10.19); P = 0.015
Unadjusted: 0.93 (0.85–
1.01); P = 0.090
IPW: 2.46 (1.17–5.17); P = 0.017 IPW: 5.46 (1.87–15.95); P = 0.002
IPW: 0.91 (0.82–1.02); P 
= 0.096
Confirmed virologic failure without prior 
immunologic failure (N = 610)i
Unadjusted: 1.31 (0.63– 2.72); P 
= 0.47
Unadjusted: 2.60 (0.82–
8.24); P = 0.10
Unadjusted: 0.96 (0.91–
1.01); P = 0.14
IPW: 2.40 (0.99–5.82); P = 0.052 IPW: 3.43 (0.99–11.88); P = 0.052
IPW: 0.98 (0.93–1.03); P 
= 0.40
Confirmed virologic failure with prior viral 
suppression (N = 626)j
Unadjusted: 1.19 (0.63–2.26); P = 
0.59
Unadjusted: 3.13 (1.12–
8.69); P = 0.029
Unadjusted: 0.93 (0.86–
1.00); P = 0.054
IPW: 1.93 (0.87–4.28); P = 0.11 IPW: 4.24 (1.42–12.63); P = 0.010
IPW: 0.94 (0.87–1.01); P 
= 0.094
Nonconfirmed virologic rebound (N = 1337)k Unadjusted: 0.59 (0.33–1.06); P = 0.078
Unadjusted: 1.18 (0.43–
3.25); P = 0.76
Unadjusted: 0.97 (0.94–
1.01); P = 0.087
IPW: 0.96 (0.44–2.08); P = 0.92 IPW: 1.09 (0.30–3.95); P 
= 0.89
IPW: 0.99 (0.95–1.04); P 
= 0.77
CI, confidence interval; OR, odds ratio.
a
Inverse probability weighted (IPW) estimates adjust for measured confounders of switch and measured causes of potentially informative 
censoring using inverse probability weights.
b
P(Yswitch. time(t) = 1|Yswitch. time(t – 1) = 0) = exp it(β0 + β1|(switch.time ≥ t) + β2t).
c
P(Yswitch. time(t) = 1|Yswitch. time(t – 1) = 0) = exp it(α0 + α1|(switch. time ≥ t) + α2t + α3|(switch.time > t) × t): Corresponding mortality 
functions plotted in Figure 2.
d
exp(β1).
e
exp(α1).
f
exp(α3).
g
Follow-up until death, database closure or reported transfer. Mean weights = 0.93; range: 0.02-10.
h
Follow-up until death, database closure, reported transfer or 270 days without recorded visit. Mean weights = 0.91; range: 0.001-18.
i
Patients had not met any of WHO immunologic failure criteria at or before time of confirmed virologic failure. Follow up until death, database 
closure or reported transfer. Mean weights = 1.05; range: 0.03-22.
j
Patients with at least one HIV RNA level <400 copies/ml prior to confirmed virologic failure. Follow up until death, database closure, or reported 
transfer. Mean weights = 0.94; range: 0.10-17.
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kNonconfirmed rebound defined as an HIV RNA level ≥400 copies/ml, preceded by at least one HIV RNA level <400 copies/ml. Follow-up until 
death, database closure or reported transfer. Mean weights = 0.96; range: 0.10-8.
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